Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Induction of Neo-Antigen Specific Cytotoxic T Cells by Autologous Tumor Lysate-loaded Specialized Cross-Presenting Dendritic Cells in Epithelial Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy, the NEODOC Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.

Who May Be Eligible (Plain English)

Inclusion criteria - Women over 18 years old with diagnosed by tissue sample (biopsy-confirmed) primary epithelial ovarian cancer. - Not amenable by primary debulking surgery and in need of neoadjuvant chemotherapy and interval debulking - High-grade or low grade serous histology - FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes ≤ 1cm above the diaphragm or in the groins - Extensive abdominal spread of tumor - WHO/You should be able to carry out daily activities with 0 level of ability (ECOG 0)-1 - Neutrophils \>1.5x 109/L, platelets \>100x 109/L, hemoglobin \>5,6 mmol/L (9.0 g/dl), estimated glomerular filtration rate \> 45 ml/min/1.73m2 , AST/ALT \<3 x ULN, serum bilirubin \<1.5 x ULN (exception: Gilbert's syndrome is permitted) - Expected adequacy of follow-up - Postmenopausal or evidence of non-childbearing status or for women of childbearing potential: negative urine or serum pregnancy test, within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as: - Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments; - or surgical sterilisation (bilateral oophorectomy or hysterectomy). - willing to sign a consent form Exclusion criteria - Recurrent ovarian cancer - Histologies other than high grade serous ovarian cancer such as, but not restricted to, endometrioid, mucinous, clear cell or carcinosarcoma - Unable and/or unwilling to undergo standard chemotherapy and interval debulking surgery - FIGO stage I-IIb, IIIa or IVb with liver, spleen or lung metastases or lymph nodes above the diaphragm or in the groins \> 1 cm - History of any second malignancy, with the exception of adequately treated basal cell carcinoma, cervical cancer \> 5 years ago or early stage breast cancer \>10 years ago. - Any serious clinical condition that may interfere with the safe administration of DC vaccinations - Heart failure (NYHA class III/IV) ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria * Women over 18 years old with histologically confirmed primary epithelial ovarian cancer. * Not amenable by primary debulking surgery and in need of neoadjuvant chemotherapy and interval debulking * High-grade or low grade serous histology * FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes ≤ 1cm above the diaphragm or in the groins * Extensive abdominal spread of tumor * WHO/ECOG performance status 0-1 * Neutrophils \>1.5x 109/L, platelets \>100x 109/L, hemoglobin \>5,6 mmol/L (9.0 g/dl), estimated glomerular filtration rate \> 45 ml/min/1.73m2 , AST/ALT \<3 x ULN, serum bilirubin \<1.5 x ULN (exception: Gilbert's syndrome is permitted) * Expected adequacy of follow-up * Postmenopausal or evidence of non-childbearing status or for women of childbearing potential: negative urine or serum pregnancy test, within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as: * Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments; * or surgical sterilisation (bilateral oophorectomy or hysterectomy). * Informed consent Exclusion criteria * Recurrent ovarian cancer * Histologies other than high grade serous ovarian cancer such as, but not restricted to, endometrioid, mucinous, clear cell or carcinosarcoma * Unable and/or unwilling to undergo standard chemotherapy and interval debulking surgery * FIGO stage I-IIb, IIIa or IVb with liver, spleen or lung metastases or lymph nodes above the diaphragm or in the groins \> 1 cm * History of any second malignancy, with the exception of adequately treated basal cell carcinoma, cervical cancer \> 5 years ago or early stage breast cancer \>10 years ago. * Any serious clinical condition that may interfere with the safe administration of DC vaccinations * Heart failure (NYHA class III/IV) * Any uncontrolled co-morbidity, e.g. psychiatric or social conditions interfering which participation * Unable to undergo a tumor biopsy * Pregnancy or insufficient anti-conception if reproduction is still possible * Active infection of Hepatitis B, C, HIV and syphilis * Serious other active infections * Known allergy to shell fish * Auto immune disease (exception: vitiligo is permitted) * History of organ allografts * Chronic treatment with systemic immunosuppressive drugs (i.e. more than 10 mg prednisolone equivalent)

Treatments Being Tested

BIOLOGICAL

XP-DC vaccinations

Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH

Locations (1)

Radboud University Medical Center
Nijmegen, Gelderland, Netherlands